NCT07487766尚未招募1 期
A Phase 1/2, Single-Blinded Trial to Evaluate the Safety and Efficacy of Intra-Articular (IA) Injection of XytriX in Adult Subjects With Grade I-IV Knee Osteoarthritis (KOA)
TricelX Inc.1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2026年5月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Knee Injury and Osteoarthritis Outcome Score
研究概览
简要总结
This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to be eligible for enrollment:
- •Adult patient aged 18 years or older with Grade I-IV knee osteoarthritis as determined by radiographic (X-ray) evaluation.
- •Ambulatory subject with symptoms of knee osteoarthritis for at least 3 months, who may be receiving conservative therapy (e.g., oral anti-inflammatory medication) and/or physical therapy. In subjects with bilateral knee OA, the more symptomatic knee will be designated as the target knee.
- •Subject with joint pain equal to or greater than 7 (out of a total pain score of 24 points) on the target knee as assessed by the WOMAC pain subscale.
- •Subject or legal representative is willing and able to provide written informed consent after reading the informed consent form (ICF) and having the opportunity to discuss the study with the investigator or designee.
- •Women of childbearing potential must have a negative urine pregnancy test prior to treatment administration. Women of childbearing potential and males who are heterosexually active with a female of childbearing potential must agree to use a double barrier method of contraception for at least 4 weeks following administration, unless the female partner is post-menopausal (defined as 12 months of spontaneous amenorrhea, or 6 months amenorrhea with FSH >40 mIU/mL) or has undergone surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation.
排除标准
- •Subjects meeting any of the following criteria will be excluded from participation:
- •Suspected or confirmed pregnancy, or planning to become pregnant within 2 years of treatment.
- •Body mass index (BMI) over 40 kg/m². Knee deformity (varus or valgus greater than 10 degrees) on the target knee. Acute inflammation, tense effusion (e.g., infection), or active bleeding on the target knee as judged by the Principal Investigator (PI).
- •Ligament instability (cruciate or collateral ligaments) or ligament laxity of the target knee as judged by the PI.
- •History of surgery, articular injury, ligament reconstruction, or meniscus repair on the target knee within the previous 6 months.
- •History of arthroscopic surgery in the target knee in the past 6 months, or planned arthroscopy or knee replacement during the trial period.
- •History of total knee replacement procedure on the target knee. Intra-articular injection of any treatment (hyaluronic acid, corticosteroids, or platelet-rich plasma [PRP]) on the target knee in the last 3 months prior to enrollment.
- •Known history of osteoarthritis of the hip or ankle. Known history of any systemic autoimmune rheumatic disease, including but not limited to: rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease (IBD), sarcoidosis, lymphoma, or amyloidosis.
- •Active malignancy or treatment for cancer within the past year. Active systemic infection. Known HIV infection. Active hepatitis B or active hepatitis C. Immunocompromised state. Significant concomitant illness as judged by the PI. Hemodynamic instability. Chronic multi-system organ failure. Organ transplant history. Known allergy or hypersensitivity to any component of the investigational product, including DMSO, cell therapies, or hyaluronic acid. Subjects with known sulfur hypersensitivity are specifically excluded due to the DMSO in the cryoprotectant.
- •Known allergy or hypersensitivity to any concomitant or rescue medications. Significant skin disease at the injection site on the target knee as judged by the PI.
- •Participation in another clinical trial or treatment (immunosuppressant therapies, systemic steroids, cytotoxic drugs, chemotherapy, radiation therapy, new investigational drugs or cell therapy) within 3 months prior to enrollment.
- •Inability to provide informed consent or to have a legal representative provide informed consent.
- •Medical condition that would, in the opinion of the investigator, compromise the patient's safety or ability to comply with study procedures.
研究组 & 干预措施
XytriX 30 million cells intra-articular injection
Experimental
Subjects in this arm are receiving the drug at a 30 million cells IA dose.
干预措施: Mesenchymal Stem Cell Injection (Biological)
XytriX 10 million cells IA Injection
Experimental
干预措施: Mesenchymal Stem Cell Injection (Biological)
XytriX 50 million cells IA dose
Experimental
干预措施: Mesenchymal Stem Cell Injection (Biological)
结局指标
主要结局
Knee Injury and Osteoarthritis Outcome Score
时间窗: 24 months
Scores are transformed into a 0-100 point scale. 0 means extreme problems and 100 means no problems.
Western Ontario and McMaster Universities Osteoarthritis Index
时间窗: 24 months
Items are typically scored on a 0-4 Likert scale: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). Lower scores indicate better outcomes, while higher scores indicate worse pain, stiffness, and functional limitations.
Knee Injury and Osteoarthritis Outcome Score
时间窗: 6 months
Western Ontario and McMaster Universities Osteoarthritis Index
时间窗: 6 months
次要结局
- Visual Analog Pain Score(24 months)
- KOOS Sub-Scale(24 months)
- Short Form-36 (SF-36)(24 months)
- Timed Up and Go Test(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)ThrombocytopeniaNCT07441720Zhejiang Cancer Hospital25
Enrolling By Invitation
1 期
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAASevere Aplastic AnemiaNCT07299123Chinese PLA General Hospital40
尚未招募
3 期
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).Acute Respiratory Distress SyndromeNCT07479043Breathe Biologics, Inc.128
招募中
1 期
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart FailureChronic Heart FailureNCT07265349Tasly Pharmaceutical Group Co., Ltd51
招募中
1 期
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress SyndromeAcute Respiratory Distress SyndromeNCT07413978Changchun Tuohua Pharmaceutical Co., Ltd.36